Golden
Cynapsus Therapeutics

Cynapsus Therapeutics

Cynapsus Therapeutics is a pharmaceutical subsidiary of Sunovion developing a non-injectable rescue therapy for Parkinson’s disease symptoms. The company was founded in 2004 and is headquartered in Toronto, Ontario, Canada.

Cynapsus Therapeutics is a specialty pharmaceutical company developing oral drug treatments for Parkinson's disease. Cynapsus Therapeutics was founded in 1984 by Anthony Giovinazzo and is headquartered in Toronto, Ontario, Canada.

Products

APL-130277

Cynapsus Therapeutic's drug candidate for the treatment of Parkinson's disease is called APL-130277 and is a sublingual form of apomorphine; a common drug used to treat Parkison's disease that is administered to patients through the gastrointestinal system. 

Acquired by Sunovion Pharmaceuticals

On September 1, 2016 Sunovion Pharmaceuticals acquired Cynapsus Therapeutics to expand its own drug portfolio to treat diseases on the central nervous system. Sunovion Pharmaceuticals purchased Cynapsus Therapeutics for approximately $624 million at $40.50 per share in cash.

Timeline

People

Name
Role
LinkedIn

Andrew Williams

COO & CFO



Anthony J. Giovinazzo

President & CEO, Director



David J. Duff

Employee



Dawson Sprigings

Employee



Dr. Albert Agro

Chief Medical Officer



Kristen Galfetti

Vice President Relations & Corporate Communications



Thierry Bilbault

Chief Scientific Officer and Executive Vice President of Chemistry, Manufacturing, and Controls



Further reading

Title
Author
Link
Type
Date

Why Cynapsus Therapeutics (CYNA) Stock Is Soaring Today

Rachel Aldrich

Web



Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References